Indium In 111-DOTA-Daratumumab

Phase 1Monoclonal antibody

Indium In 111-DOTA-Daratumumab is one of 77 biologic programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaRecruiting

Multiple MyelomaRecruiting

Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

TALVEY

Johnson & Johnson

Phase 3

24 4

Venclexta

AbbVie

Phase 3

17 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 7

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 8

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 3

6 9

Daratumumab SC

Johnson & Johnson

Phase 3

5 10

Velcade

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Multiple Myeloma

NCT05363111

Q2 2027

Phase 1Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05139004

Q2 2028

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06287944

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting·CCity of Hope Medical Center·Phase 1·NCT06287944·15 enrolled

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT05139004·7 enrolled

Multiple Myeloma1 trial

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 1·NCT05363111·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Indium In 111-DOTA-Daratumumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indium In 111-DOTA-Daratumumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indium In 111-DOTA-Daratumumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

Indium In 111-DOTA-Daratumumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2028

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News